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The ebolavirus VP35 protein antagonizes the cellular type I interferon response by blocking phosphorylation of IRF-3, a transcription
factor that turns on the expression of a large number of antiviral genes. To identify the domain of VP35 responsible for interferon antagonism,
we generated mutations within the VP35 gene and found that a C-terminal basic amino acid motif is required for inhibition of ISG56 reporter
gene expression as well as IFN-h production. Remarkably, this basic amino acid motif displayed high sequence identity with part of the N-
terminal RNA-binding domain of another interferon-antagonist, the NS1 protein of influenza A virus.
Published by Elsevier Inc.
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Human infections with Zaire ebolavirus (ZEBOV) are
highly lethal and generally have a 70% to 90% case fatality
(Sanchez et al., 1996). Following infection, disease onset is
extremely rapid with death approximately 7 to 11 days after
symptoms appear (Sanchez et al., 1996). Many patients
succumb to the disease with high levels of viremia and
before the development of measurable antibody responses
(Ksiazek et al., 1999). Indeed, survivors of ebolavirus
infection tend to have lower levels of viremia and higher
levels of virus-specific antibodies than fatal cases (Ksiazek
et al., 1999; Towner et al., 2004). The primary target cells0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2004.07.006
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(Geisbert et al., 2003; Stroher et al., 2001), two critical types
of antigen presenting cells that link the innate and adaptive
arms of the immune system. Ebolavirus infection of DC
renders them incompletely activated and functionally
impaired (Bosio et al., 2003; Mahanty et al., 2003). It has
been postulated that impairment of DC function may delay
or inhibit the induction of virus-specific immunity, which is
often suppressed in fatal cases (Bosio et al., 2003; Mahanty
et al., 2003). Thus, the initial interaction of virus with its
target cells may have a profound impact on both the innate
and adaptive immune responses to infection. One of the
ebolavirus proteins, VP35, may play a key role in the
interaction of the virus with its target cells. VP35 has two
functions during viral infection: (1) it is essential for
formation of the ribonucleoprotein (RNP) complex, and is
therefore required for viral replication and transcription
(Muhlberger et al., 1999), and (2) it antagonizes the host cell
type I interferon (IFN) system (Basler et al., 2000). With04) 177–184
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of interferon regulatory factor (IRF)-3, a primary component
of the immediate early signaling cascade that initiates the
cellular antiviral response (Basler et al., 2003). IRF-3 is
activated early during virus infection by the presence of
dsRNA molecules within the cell, and it acts in conjunction
with other transcription factors to turn on the expression of
immediate early antiviral genes such as IFN-a/h, IL-15,
ISG15, and ISG56 (Grandvaux et al., 2002). Neither the
mechanism by which VP35 inhibits activation of IRF-3, nor
the regions of VP35 responsible for the antagonism are
currently known. However, other viral IFN-antagonists have
been extensively studied, one of which is the NS1 protein of
influenza A virus. NS1 inhibits the host cell IFN response
by several mechanisms that include (1) inhibition of the
processing of antiviral pre-mRNA molecules, (2) inhibition
of protein kinase R (PKR) activation, and (3) decreased
activation of the transcription factors NF-nB, IRF-3, and c-
Jun/ATF2 (Garcia-Sastre, 2001; Krug et al., 2003). Indeed,
an N-terminal RNA-binding domain and a C-terminal
effector domain of NS1 have been identified, and two
critical basic amino acids within the N-terminal RNA-
binding domain (R38 and K41) have been shown to be
involved in both RNA-binding and IFN-antagonism (Talon
et al., 2000; Wang et al., 1999). Generation of a mutant
influenza A virus that is altered at these two basic amino
acids resulted in a decreased induction of IFN in infected
cells and an attenuated pathogenicity in mice (Donelan et
al., 2003). In this study, we identified a highly conserved C-
terminal basic amino acid motif within ZEBOV VP35 that is
responsible for inhibiting IRF-3-dependent gene expression.
We also show that, remarkably, this motif displays high
identity with the N-terminal RNA-binding domain of the
NS1 protein of influenza A virus.Fig. 1. The effect of C-terminal deletion mutations on IFN-antagonism
mediated by VP35. (A) SeV induction of ISG56-luciferase expression in the
presence of an empty vector control plasmid, ebolavirus VP35, or
ebolavirus NP. Firefly luciferase activity was normalized to Renilla
luciferase, and a fold-induction value was obtained by comparing SeV-
infected wells with uninfected control wells. (B) Schematic illustration of
the 5 C-terminal deletion constructs. Full-length VP35 is illustrated on top.
Stop codons were inserted at the indicated residues. (C) Evaluation of each
deletion construct in the ISG56-luciferase reporter gene assay. Error bars
indicate the average of each construct tested in duplicate; results shown here
are representative of three independent experiments.Results
The VP35 protein of Zaire ebolavirus inhibits activation of
the IRF-3-responsive promotor, ISG56
Previous studies showed that infection of 293 T cells
with Sendai virus (SeV), a potent inducer of the type I
interferon system, activates the IFN-responsive promotor
ISG56 in an IRF-3-dependent manner, and this activation is
significantly inhibited by the presence of VP35 from
ebolavirus (Basler et al., 2003). To examine the effects of
VP35 on ISG56 promotor antagonism in our studies, we
used a similar transfection-based reporter gene assay (Basler
et al., 2000, 2003). 293T cells were transfected with an
ISG56-firefly luciferase plasmid (pISG56/pGL3b), a VP35
expression plasmid (pCEZ-VP35), and a constitutively
expressed Renilla luciferase plasmid (phRG-TK). After
induction of the interferon pathway by SeV infection, firefly
luciferase activity was measured and normalized relative to
Renilla expression. SeV infection induced approximately a10-fold increase in firefly luciferase activity in control wells,
and this expression was significantly inhibited by the
presence of VP35, but not the ebolavirus NP protein (Fig.
1A), similar to earlier findings (Basler et al., 2000, 2003).
Actual increases in luciferase expression relative to empty
Rapid Communication 179vector controls (such as that observed here with Ebola NP)
are occasionally seen with some other recombinant proteins
expressed in these cells but these do not appear to be
significant.
ISG56-promotor antagonism is eliminated by deletion of 40
C-terminal amino acids of VP35
The VP35 protein of ZEBOV is 340 amino acids in
length. To determine which regions of VP35 are responsible
for inhibiting ISG56 promotor activation, five C-terminal
deletion constructs were generated by inserting a stop codon
at the indicated position using the overlap-extension PCR
method (Fig. 1B). When each of these constructs was tested
in the reporter gene assay, all five truncated proteins lost the
ability to block ISG56 activation (Fig. 1C). The largest of
the proteins, R300T, has a stop codon inserted at arginine
300, resulting in a deletion of the C-terminal 40 amino
acids. The data suggest that these 40 residues may be
essential for VP35 to successfully inhibit ISG56 promotor
activation. A Western blot using an anti-VP35 antibody
demonstrated that the absence of inhibitory activity of the
R300T protein does not appear to be related to lack of
synthesis or instability of the truncated protein (data not
shown).
High sequence identity between the C-terminal region of
ebolavirus VP35 and the dsRNA binding domain of
influenza NS1 protein
Bioinformatic comparison of the last 40 amino acids of
VP35 with other known viral interferon antagonists
revealed that a 9-amino acid region (a.a. 304–312) shows
remarkable similarity to part of the N-terminal RNA-
binding domain of the influenza A virus NS1 protein (a.a.
36–46) (Fig. 2). No other known viral interferon antago-
nists showed any similarity with VP35. The NS1 protein
of influenza A virus has been extensively studied and is
known to inhibit the host cell type I interferon response by
several mechanisms (Garcia-Sastre, 2001; Krug et al.,
2003). For NS1, changing the arginine residue at position
38 (R38) and the lysine at position 41 (K41) to alanineFig. 2. A short C-terminal motif within VP35 displays high identity with
part of the N-terminal RNA-binding domain of influenza virus NS1 protein.
Part of the N-terminal RNA binding domain of NS1 from influenza A/
WSN/33 (M12597) compared to the C-terminal domain from Zaire
ebolavirus Mayinga VP35 (AF272001). Asterisks below NS1 sequence
indicate residues that have been shown to be responsible for RNA-binding.
Asterisks above VP35 sequence are the basic amino acids changed to
alanine residues in this study.residues completely abolished the RNA-binding capacity
and significantly reduced its interferon-antagonistic proper-
ties both in vitro and in vivo (Donelan et al., 2003; Talon
et al., 2000; Wang et al., 2000). The similarities between
VP35 and NS1 prompted further investigation into the role
of this VP35 region in inhibiting ISG56 promotor
activation.
Alanine substitution of basic amino acids within the
C-terminal region of VP35 eliminates ISG56 promotor
inhibition and restores IFN-b synthesis
Based on sequence comparisons with influenza virus
NS1, basic amino acids within the 304–312 region of
ebolavirus VP35 were substituted with alanine residues.
Substitution of arginine 305 with alanine (R305A) did not
significantly affect the ability of VP35 to inhibit ISG56
activation (Fig. 3A). However, changing arginine 312 to
alanine (R312A) eliminated most of the inhibitory activity,
and altering the lysine at position 309 (K309A) generated an
intermediate phenotype. Out of the three basic amino acids
changed to alanine, the R312A mutation resulted in the
greatest disruption to the inhibitory capacity of VP35. Thus,
of the three amino acids studied here, R312 appeared to be
the most important amino acid for inhibiting ISG56
promotor activation.
Two double alanine substitutions were also created,
generating the R305A/K309A and K309A/R312A con-
structs. Not surprisingly, the inhibitory activity of the
K309A/R312A mutant was completely abolished (Fig.
3A). Interestingly, the R305A/K309A mutant was also
completely unable to inhibit reporter gene expression.
Therefore, while neither R305A nor K309A substitutions
alone were able to eliminate the inhibition, the inhibitory
action was completely eliminated in the doubly substituted
protein (Fig. 3A). Western blots using a monoclonal anti-
VP35 antibody revealed that all of the mutated proteins are
expressed at similar levels, indicating that these results
cannot be attributed to a lack of expression (data not
shown).
To examine the effect of these alanine substitutions
within VP35 on a more direct measurement of the cellular
interferon response, an IFN-h ELISA was used to measure
the amount of IFN-h secreted into the supernatant of
transfected 293 T cells. VP35-expressing cells secreted 6-
fold less IFN-h than control wells transfected with the
empty vector (Fig. 3B), which is very similar to results
seen with the luciferase reporter gene (Fig. 3A). Cells
transfected with the R312A construct, the two double
alanine constructs, and the R300T truncated construct all
secreted high levels of IFN-h that were similar to control
wells, indicating that these proteins were unable to block
IFN-h synthesis. As was seen in the luciferase reporter
gene results, the R305A and K309A constructs were both
associated with low levels of IFN secretion on par with the
wild-type VP35 (Fig. 3B).
Fig. 3. Substitution of basic amino acids within the C-terminal region of VP35 to alanine residues eliminates ISG56 promotor inhibition and results in increased
IFN-h production. (A) VP35 expression constructs with alanine substitutions were tested in the ISG56-reporter gene assay and compared with wild-type VP35
and an empty vector control. The C-terminal deletion mutant, R300T, was also included for comparison purposes. Error bars indicate the average of each
construct tested in duplicate; results shown here are representative of three independent experiments. (B) An ELISA for human IFN-h was performed using
supernatants from transfected 293T cells described above. Error bars indicate the average result from each construct tested in quadruplicate; results shown here
are representative of two independent experiments.
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highly conserved among Filovirus sequences
Previous comparisons of the VP35 amino acid sequences
from ebolavirus and Marburg virus show an overall identity
of 33% (Bukreyev et al., 1993). An alignment of VP35 amino
acid sequences from isolates of both ebolavirus as well as
Marburg virus revealed that the N-terminal region is quite
divergent, even between the Zaire and Reston ebolaviruses
(Fig. 4). However, the C-terminal half is more conserved,
with some small regions showing complete conservation
between ebolavirus and Marburg virus genera (Fig. 4).
Indeed, residues R305, K309, and R312 fall in a region that
is highly conserved among all the known VP35 sequences.
These comparisons suggest that these residues may play acritical role in the global function of VP35 from all members
of the Filoviridae family.Discussion
For several years, it has been known that ebolavirus
likely encodes an antagonist of the cellular type I
interferon response. Initially, it was shown that infected
endothelial cells are less responsive to IFN, and dsRNA-
dependent induction of interferon-stimulated genes (ISGs)
is blocked by ebolavirus infection (Harcourt et al., 1999).
Subsequently, Basler et al. (2000) used a mutant
influenza A virus lacking the NS1 gene (delNS1) to
show that the VP35 protein of ZEBOV could rescue the
Fig. 4. Comparison of VP35 amino acid sequences. The top six sequences (GenBank accession numbers shaded in blue) correspond to Zaire ebolavirus
isolates. Below, Reston ebolavirus sequences are shown in red, and Marburg virus sequences are shown in green. Amino acids with black background represent
conserved residues. Red bracket indicate the basic motif, and amino acids 305, 309, and 312 with respect to Zaire ebolavirus sequences are indicated by red
asterisks.
Rapid Communication 181growth of delNS1 in tissue culture. In addition, VP35
was able to block ISRE- and IFN-h-promotor-driven
reporter gene expression, as well as block the production
of IFN in response to dsRNA. A subsequent studyrevealed that VP35 did not interfere with signaling from
the IFN-a/h receptor; rather, it blocked phosphorylation
of IRF-3, a transcription factor that acts immediately after
viral infection to turn on the expression of several
Rapid Communication182antiviral genes, including IFN-h itself (Basler et al.,
2003).
Before our study, little was known about the regions of
VP35 responsible for its two primary functions: RNP
complex formation and IFN antagonism. To address this
issue, we created a series of truncated VP35 constructs,
which revealed that removing the C-terminal 40 amino
acids of VP35 completely alleviated the block on ISG56
promotor activation, suggesting this region of the protein
was critical for IFN antagonism. By comparing this C-
terminal region of VP35 with other known viral IFN-
antagonists, we found significant identity between a.a.
304–312 of VP35 and a portion of the N-terminal RNA-
binding domain of the influenza virus A NS1 protein. The
similarity of these two proteins within this short region
suggests they may have a similar function. This is not
surprising given the fact that VP35 was able to comple-
ment the growth of the mutant delNS1 influenza A virus
(Basler et al., 2000).
To investigate the significance of these similarities, several
basic amino acids within this region or identity were changed
to alanine residues. Our results show the arginine residue at
position 312 to be the most critical single residue required for
VP35 to effectively block activation of an IRF-3 responsive
promotor. ISG56 reporter gene expression and IFN-h
secretion were restored to control levels when we changed
this one amino acid to alanine. Two other amino acids (R305
and K309) had little effect on VP35 function when changed
alone, but together, they resulted in a VP35 protein that could
not inhibit reporter gene expression or IFN-h production.
Studies with NS1 have shown that it is a dimeric protein
that binds non-specific RNA in vitro with low affinity (Wang
et al., 1999). Within the 73-amino acid N-terminal RNA-
binding domain, substitution of the highly conserved residues
R38 and K41 with alanines prevented RNA binding,
destroyed some of the ability to antagonize IFN, and rendered
a recombinant influenza A virus containing these mutations
attenuated in mice (Donelan et al., 2003; Wang et al., 1999).
Our study of ebolavirus VP35 together with previous studies
on NS1 show that the ability of both proteins to antagonize
IFN is mediated at least in part through the short region of
sequence identity.
There are several reasons why mutation of these
particular basic amino acids within VP35 eliminates IFN
antagonism. Mutation of the basic amino acids within the
304–312 region of VP35 may physically disrupt its ability
to block IRF-3 activation. The mechanism by which VP35
prevents IRF-3 activation is unknown; however, VP35 may
interact directly with IRF-3, or with an upstream member of
the signaling cascade that activates IRF-3, such as IKKq or
TBK-1 (Fitzgerald et al., 2003). Alternatively, based on
similarities with NS1, VP35 may bind RNA through this
region, and RNA binding may be necessary for IFN
antagonism. Therefore, changing these amino acids may
eliminate the RNA binding function of VP35 and hence IFN
antagonism as well.Aside from IFN-antagonism, an essential function of
VP35 is to form, along with the viral NP, L, and VP30
proteins, the functional RNP complex necessary for viral
replication (Muhlberger et al., 1999). It is possible that
changing R305, K309, and R312 alters the ability of VP35 to
form a functional RNP complex as well as its ability to
antagonize IFN. We are currently investigating whether the
domains of VP35 that are responsible for IFN antagonism are
also involved in RNP complex formation.
Ebolavirus-infected patients succumb to disease with
high levels of viremia and little or no measurable adaptive
immune responses (Ksiazek et al., 1999; Towner et al.,
2004). Early infection of macrophages results in secretion of
a large number of inflammatory mediators which are
thought to contribute to the characteristic endothelial cell
damage seen with this disease (Gupta et al., 2001; Stroher et
al., 2001). Infection of dendritic cells, another initial target
of ebolavirus, renders them dysfunctional and incompletely
activated (Bosio et al., 2003; Mahanty et al., 2003), which
may serve to delay or inhibit in the subsequent induction of
virus-specific immunity (Bosio et al., 2003; Mahanty et al.,
2003). Because VP35 can suppress the induction of antiviral
proteins as well as the induction of an antiviral state in
neighboring cells, it may play an important role in the
interaction between ebolavirus and these critical antigen
presenting cells.
In this study, we have shown that a highly conserved
basic amino acid motif within the C-terminal region of
ZEBOV VP35 plays a critical role in the ability of this
protein to antagonize IFN. Mutation of R312 by itself, or
R305 and K309 in combination, resulted in a restoration of
ISG56 promotor activation and IFN-h production after
Sendai virus infection of transfected 293 T cells. The VP35
protein of ebolavirus is clearly a virulence factor because of
its ability to inhibit the interferon pathway. Continued study
of the role of VP35 in viral replication and pathogenesis
may lead to a better understanding of the complex interplay
between this virus and its host that results in such a severe
and deadly disease.Materials and methods
Cells, viruses, and plasmids
293T cells were propagated in Dulbecco’s Modified
Eagle Medium (DMEM) containing 10% fetal bovine serum
(FBS) supplemented with penicillin/streptomycin. Sendai
virus (Cantell strain) was obtained from ATCC and
propagated in 10-day-old embryonated chicken eggs. The
VP35 expression plasmid pCEZ-VP35 was obtained from
Y. Kawaoka, and the ISG56-luciferase plasmid (p1SG56/
pGL3b) was obtained from J. Hiscott. The VP35 gene was
cloned into the pcDNA3.1 vector for mutagenesis studies.
Site-directed mutagenesis was performed by overlap exten-
sion (Sambrook and Russell, 2001). Human IFN-h ELISAs
Rapid Communication 183(Biosource) were performed according to the manufacturer’s
instructions.
Luciferase reporter gene assays
293T cells were transfected in suspension by the calcium
phosphate method (Sambrook and Russell, 2001). Briefly,
cells were transfected with the following: (1) 2 Ag of pCEZ-
VP35; (2) 150 ng of pISG56/pGL3b; (3) 150 ng of phRG-TK
(Promega); and (4) 4.4 Ag of salmon testes carrier DNA.After
diluting the combined plasmid DNA to 110 Al in sterile water,
125 Al of 2HEPES-buffered saline was added, followed by
15.5 Al of 2 M CaCl2 added dropwise with gentle shaking.
The DNA mixture was allowed to sit at room temperature for
30 min before using it to resuspend a cell pellet containing
approximately 0.5–1.0  106 cells. The mixture of cells and
DNA complexes was incubated at room temperature for 15
min, at which time 2.3 ml of DMEM/10% FBS/Pen-Strep
was added, and the cells were transferred to 6-well plates for
incubation at 37 8C.
Twenty-four hours following transfection, the cells were
infected with 1024 HAU of Sendai virus per well. For each
well, 50 Al of virus was diluted in PBS/BA (Dulbecco’s PBS
w/Ca2+/Mg2++, 0.2% Bovine Albumin, Penicillin/Strepto-
mycin) to a total volume of 600 Al. The media from each well
was removed, and the cells were washed once with PBS
before adding 600 Al of virus mixture. The plates were
incubated at room temperature for 1 h, at which time the
inoculum was removed and replaced with 2.3 ml of DMEM
containing 0.2% BA and Penicillin-streptomycin. After 18–
20 h at 37 8C, the cells were harvested in 500 Al of passive
lysis buffer, and 20 Al of each sample was tested in the Dual-
luciferase assay according to the manufacturer’s instruction
(Promega). The firefly luciferase values were normalized to
the Renilla values for each sample. The relative fold-
induction of reporter gene expression was assessed by
comparing SeV-infected wells versus uninfected control
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